Novartis has entered a significant licensing and collaboration agreement with Arrowhead Pharmaceuticals, investing $200 million upfront to develop Arrowhead's preclinical siRNA therapy targeting alpha-synuclein for Parkinson’s disease and other synucleinopathies. This partnership includes potential milestone payments exceeding $2 billion and royalties, with Novartis undertaking late-stage development and commercialization. Arrowhead will handle preclinical requirements. This move underscores Novartis's commitment to RNAi therapeutics and builds on its previous Parkinson’s efforts.